H.C. Wainwright Sticks to Its Buy Rating for Aurinia Pharmaceuticals (AUPH)

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on Aurinia Pharmaceuticals (AUPHResearch Report) today and set a price target of $14.00. The company’s shares closed last Friday at $5.15.

According to TipRanks, Arce is a 4-star analyst with an average return of 4.0% and a 35.57% success rate. Arce covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Aurinia Pharmaceuticals, and Cidara Therapeutics.

In addition to H.C. Wainwright, Aurinia Pharmaceuticals also received a Buy from RBC Capital’s Douglas Miehm in a report issued on November 4. However, on the same day, Oppenheimer downgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) to a Hold.

See the top stocks recommended by analysts >>

The company has a one-year high of $32.49 and a one-year low of $4.82. Currently, Aurinia Pharmaceuticals has an average volume of 2.32M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Read More on AUPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed